Kraków, Poland – November 30, 2016 – Selvita will present posters reporting results from two of its most advanced research programs at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, taking place on November 29, 2016, in Munich, Germany.The following posters will be presented at the Molecular Targeted Agents II session, on Thursday, December 1:
- SEL120−34A, a specific, potent and orally bioavailable inhibitor of CDK8, targets STAT-dependent gene transcription in leukemia and lymphoma models, poster board: P081, abstract #402.Poster reports the most recent results in the SEL120 project, showing that SEL120-34A shows high efficacy in leukemia models in vitro and in vivo, as well that the presented novel mechanism of action of the inhibitor involves changes in STAT-dependent gene transcription linked to inflammation and differentiation. Whats more, SEL120-34A shows favorable pharmacokinetic profile and safety indicating high therapeutic potential.
- Development of selective MELK kinase inhibitors for breast cancer treatment, poster board: P132, abstract #453.Poster reports the most recent results of the program developed in cooperation with H3 Biomedicine, from Cambridge, MA.
To get in touch with Selvita delegates at 2016 EORTC-NCI-AACR Symposium, please contact us at: email@example.com, or +48 12 297 47 00.